BCL2L11 and cancer: Once the mechanisms by which MYC causes an increase in BIM and PUMA are understood, it may become possible to manipulate this process to increase the levels of these pro-apoptotic BH3-only proteins in malignant cells for therapeutic benefit, either alone or in combination with anti-cancer agents, such as BH3-mimetic drugs.